Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis. Among patients with ...

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...

Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and ...

Source: Getty Images Primary myelofibrosis is a rare cancer. In the United States (US), the annual incidence is approximately 0.3 cases per 100,000 individuals. The median age of patients with ...

For the last few decades, JAK inhibitors have been the mainstay treatment for patients who have been diagnosed with myelofibrosis. The treatment landscape of myelofibrosis has undergone a significant ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According to GlobalData, Phase III drugs for ...

Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a German study showed.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...